Cancer Vaccines Market: Growth, Size, Share, and Trends

Report Code PH 9230
Published in Dec, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Cancer Vaccines Market by Type (Preventive, Therapeutic (Neoantigen)), Technology (Cell-based Vaccine, Recombinant), Indication (Cervical, Prostate), ROA (Intramuscular, Intravenous), End User (Hospitals, Speciality Clinics) - Global Forecast to 2032

Overview

The global cancer vaccines market, valued at US$9.70 billion in 2023, is forecasted to grow at a robust CAGR of 5.4%, reaching US$9.84 billion in 2024 and an impressive US$15.00 billion by 2032. The cancer vaccines market is growing rapidly, fueled by the rising prevalence of cancer, technological advancements in immunotherapy, and increasing adoption of preventive healthcare across the globe. Increased adoption of HPV vaccines for cervical cancer cases and the emergence of neoantigen-based and mRNA vaccines are likely to contribute towards market growth. Investments in R&D and strategic partnerships, such as Moderna’s collaborations in oncology, accelerate innovation in the cancer vaccine field. A robust product pipeline (mRNA-4157, Tedopi, GLSI-100 and among others) will likely contribute to market growth in the coming years.

Cancer Vaccines Market– Global Forecast and Key Opportunities to 2032

Attractive Opportunities in the Cancer Vaccines Market

Asia Pacific

The high market share of the Asia Pacific can be attributed to its increasing healthcare expenditure, rising incidence and prevalence of cancer, and growing public awareness.

Increased investments into neoantigen cancer vaccine R&D and technological advancements in immunotherapy drive the growth of the cancer vaccines market.

Collaborations & partnerships and the use of artificial intelligence & machine learning are expected to provide lucrative opportunities for market players.

The North American cancer vaccines market is expected to grow at a CAGR of 7.3% during the forecast period.

Personalized medicine and heterogeneity of cancer types and competition from alternative therapies raise challenges to market growth.

Global Cancer Vaccines Market Dynamics

DRIVER: Increased investments in neoantigen cancer vaccine R&D

Investments in clinical and preclinical R&D for neoantigen cancer vaccines are reshaping the market. Neoantigen cancer vaccines are among the most personalized immunotherapies as they target unique mutations of an individual’s cancer cells. The introduction of immunotherapy along with neoantigen cancer vaccines offers a targeted means of minimizing off-target effects and enhancing efficacy by attempting to focus on tumor-specific antigens. The influx of public and private funding for neoantigen research offers an impetus for market growth. This is largely because of the push for immunotherapy advances, the high demand for personalized cancer treatment, and the productive collaborations between biotech and pharmaceutical companies.

Neoantigen-based cancer vaccines are one of the most promising sectors in the market and have garnered attention from investors and strategic partners. The partnership between Moderna and Merck to develop mRNA-based personalized cancer vaccines is one example. In its Phase 2b trial, this experimental vaccine, mRNA-4157/V940, showed durable efficacy as a combination with pembrolizumab, a PD-1 inhibitor. In patients treated with that combination, fatality risk significantly diminished concerning high-risk melanoma. After these promising results emerged, Merck exercised its co-development and co-commercialization option on that vaccine. In 2022, Merck further invested USD 250 million, besides its original commitment, strengthening their partnership. This large investment represents a major step for neoantigen cancer vaccines and reinforces the potential role of mRNA technologies in transforming oncology. The partnership between Moderna and Merck has enhanced interest in neoantigen-based therapies and attracted the industry’s attention in propelling growth.

RESTRAINT: High development and manufacturing costs

High development and manufacturing costs slow the pace of growth in the cancer vaccines segment. The vaccine development process is complex, considering the lengthy R&D span, stringent regulation, and advanced production technologies. Such expenses limit the pipeline-to-market pathway and extend the time horizon for product launches while creating significant entry barriers to potential new entrants. Addressing all cost-centric concerns is imperative to allow for the sustained growth of cancer vaccines.

Cancer vaccines are developed by identifying and selecting substances that provoke an immune response towards tumor-specific antigens, like neoantigens, which are unique to individual tumors. This requires advanced genomic technologies like next-generation sequencing (NGS), which are capital-intensive and time-consuming. The personalized immunotherapies involving therapeutic vaccines demand precision in identifying and validating neoantigens, making their development exorbitantly costly. On the other hand, the clinical trials of cancer vaccines involve enormous multi-phase, sample-pool testing to showcase safety and efficacy. A single vaccine may take 10–15 years to reach the market, with costs ranging from USD 200 million to over USD 1 billion. The high attrition rate of clinical trials further amplifies financial risks. According to industry reports, only a fraction of cancer vaccine candidates progress beyond Phase II trials, resulting in sunk costs for unsuccessful candidates.

 

OPPORTUNITY: Collaborations and strategic partnerships

Collaboration and strategic partnerships are particularly important elements that shape the cancer vaccine market while driving innovation, speeding up drug development, and broadening market access. Blending resources from pharmaceutical firms, biotech, academic institutions, and public agencies enables overcoming the scientific and logistical constraints in vaccine development. Development partnerships yield synergistic advantages to help prosper market growth and aid innovation by combining resources, sharing risks, and deploying complementary capabilities.

Formerly, the strategic alliances between small biotech companies and large pharmaceutical companies allowed small firms to benefit from increased resource expenditure, expertise, and funding that make the development and commercialization of innovative cancer vaccines possible. Accordingly, the partnership highlights the collaboration between BioNTech and Genentech, focusing on mRNA-based personalized cancer vaccines. The collaboration will work toward jointly advancing the research, development, production, and commercialization of personalized mRNA-based vaccines that target cancer neoantigens for individual patients. Within this partnership, in October 2021, BioNTech announced that it had commenced a Phase 2 clinical trial, the HRB-2021 trial for colorectal cancer, based on a personalized treatment approach.

CHALLENGES: Personalized medicine and heterogeneity of cancer types

The cancer vaccines market is beset with challenges arising from the unique intricacy of personalized medicine and the variability of cancer entities. Personalized medicine changed the treatment of cancer by adapting therapies to the tumor genetic/molecular profile of every tumor. On the other hand, this method, in isolation, has its limitations from a logistical and technical standpoint that hinder its scalability and market reach. Because of the intrinsic heterogeneity of cancer mutations in patients (within the same cancer type), individual unique tumor antigen (neoantigen) targeted vaccines must be created. The discovery of these neoantigens demands sophisticated tools, including next-generation sequencing (NGS) and computational prediction models, which are demanding and expensive. In addition, the deep research and clinical testing required to ensure the efficacy and safety increase the time to bring a product to market, thereby further straining growth.

Global Cancer Vaccines Market Ecosystem Analysis

The cancer vaccines market operates within a complex ecosystem with many stakeholders, each playing a crucial role in developing and adopting cancer vaccines. This ecosystem encompasses cancer vaccine product providers, pipeline players, regulatory bodies, and end users. Prominent companies in the market include companies operating for several years that possess diversified product portfolios, strong global sales, and marketing networks.

Cancer Vaccines Market
 

Preventive cancer vaccines dominated the cancer vaccines market in 2023.

Based on type, the market is segmented into therapeutic (neoantigen cancer vaccines and others) and preventive vaccines. Preventive vaccines dominated the market in 2023. Their large share is attributable to their proven efficacy in reducing cancer incidence, broad applicability in immunization programs, and strong public health & government support. Due to the emergence of personalized immunotherapy, especially mRNA platforms and tumor-stripped antigen discovery through NGS, therapeutic cancer vaccines will experience the greatest growth (2024–2032). The substantial increase in cancer incidence, the need for recurrence prevention, and favorable legislation drive the market. High R&D investments and biotech partnerships will also favor market growth.

The intramuscular route of administration segment is likely to grow at a significant CAGR from 2024 to 2032.

The route of administration segment is segmented into intramuscular and other routes of administration. The intramuscular segment accounted for the largest share of the market due to its established efficacy, ease of administration, and widespread adoption in immunization programs. The intramuscular route exhibits dominance over the market of cancer vaccines as it provides superior immunogenicity and effective delivery to dendritic cells, thus inducing a better immune response. It can offer precise doses while minimizing systemic side effects. This route can be considered extremely popular for both prophylactic and therapeutic vaccines. Furthermore, seamless use in combination with modern delivery platforms like mRNA and viral vectors is aiding in wider adoption.

Asia Pacific region dominated the market in 2023

Based on region, the cancer vaccines market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. Asia Pacific dominated the global cancer vaccines market and is expected to maintain a leading market share during the forecast period.

The Asia Pacific (APAC) dominates the cancer vaccines market due to increasing healthcare expenditure, rising incidence and prevalence of cancer, and growing public awareness. Countries like China and India are scaling up immunization programs and investing in local vaccine production, making APAC a key growth driver for the global market. The North American market is experiencing the fastest growth, owing to advanced healthcare infrastructure, strong R&D investments, and high awareness of cancer prevention and treatment. The region has established players like Moderna and Merck, widespread adoption of preventive vaccines such as Gardasil, and supportive government initiatives.

HIGHEST CAGR MARKET IN 2024-2032
US FASTEST GROWING MARKET IN THE REGION
Cancer Vaccines Market

Recent Developments of Cancer Vaccines Market

  • In June 2024, Moderna and Merck & Co., Inc. reported that their investigational cancer vaccine, combined with the blockbuster immunotherapy KEYTRUDA, demonstrated improved survival rates and durable efficacy in a mid-stage clinical trial. The study focused on patients with advanced melanoma, a highly aggressive and life-threatening form of skin cancer, showcasing the potential of this combination therapy to enhance treatment outcomes.
  • In May 2024, the Serum Institute of India (SII) acquired a 20% stake in IntegriMedical. This investment aims to accelerate the development and adoption of Needle-Free Injection System technology, underscoring SII’s commitment to advancing innovative, patient-friendly healthcare solutions.

Key Market Players

Want to explore hidden markets that can drive new revenue in Cancer Vaccines Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2032
Base Year Considered 2023
Forecast period 2024-2032
Forecast units Value (USD)
Segments covered Type, Technology, Route of Administration, Indication and End User
Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

 

Key Questions Addressed by the Report

Who are the key players in the cancer vaccines market?
Key players in the cancer vaccines market include Merck & Co., Inc. (US), GSK plc (UK), Dendreon Pharmaceuticals LLC (US), JW CreaGene (Korea), Serum Institute of India Pvt. Ltd. (India), Verity Pharmaceuticals, Inc. (Canada), Wantai BioPharm (China), Vaccinogen (US), and Shanghai Zerun Biotechnology Co., Ltd. (China), among others
Which type segment dominates the cancer vaccines market?
The preventive vaccines segment dominated the market in 2023.
Which technology segment of the cancer vaccines market is expected to register the highest growth?
The recombinant vaccines segment is anticipated to register the highest CAGR during the forecast period.
Which indication segment dominates the cancer vaccines market?
The cervical & related cancers segment dominated the market in 2023.
What is the size of the cancer vaccines market?
The global cancer vaccines market is anticipated to reach USD 15.00 billion in 2032 from USD 9.84 billion in 2024, with a significant CAGR of 5.4%.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Cancer Vaccines Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table Of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
26
RESEARCH METHODOLOGY
30
EXECUTIVE SUMMARY
42
PREMIUM INSIGHTS
47
MARKET OVERVIEW
50
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Increased investments in neoantigen cancer vaccine R&D
    - Technological advancements in immunotherapy
    - Increasing awareness and preventive healthcare measures
    - Rising cancer incidence globally
    RESTRAINTS
    - High development and manufacturing costs
    - Lengthy clinical trial processes & vaccine hesitancy and limited adoption
    OPPORTUNITIES
    - Collaborations and strategic partnerships
    - Incorporation of AI and big data
    CHALLENGES
    - Personalized medicine and heterogeneity of cancer types
    - Competition from alternative therapies
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 ECOSYSTEM ANALYSIS
    RAW MATERIAL PROVIDERS
    PRODUCT PROVIDERS
    END USERS
    REGULATORY LANDSCAPE
  • 5.6 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - mRNA-based vaccines
    - Dendritic cell vaccines
    - Recombinant vector-based vaccines
    COMPLEMENTARY TECHNOLOGIES
    - Artificial Intelligence (AI) and Machine Learning (ML)
    - Adjuvants for immuno-stimulation
    ADJACENT TECHNOLOGIES
    - CAR T-cell therapy
    - CRISPR-based gene editing
  • 5.7 PATENT ANALYSIS
    METHODOLOGY
    NUMBER OF PATENTS FILED
    INNOVATIONS AND PATENT APPLICATIONS
  • 5.8 PRICING ANALYSIS
    AVERAGE SELLING PRICE TREND OF KEY PLAYERS, 2021–2023
    AVERAGE SELLING PRICE, BY REGION, 2023
  • 5.9 KEY CONFERENCES & EVENTS, 2024–2O25
  • 5.10 REGULATORY LANDSCAPE
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    REGULATORY FRAMEWORK
    - North America
    - Europe
    - Asia Pacific
  • 5.11 INVESTMENT & FUNDING SCENARIO
  • 5.12 PORTER’S FIVE FORCES ANALYSIS
    INTENSITY OF COMPETITIVE RIVALRY
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    THREAT OF SUBSTITUTES
    THREAT OF NEW ENTRANTS
  • 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS
    KEY BUYING CRITERIA
  • 5.14 TRADE ANALYSIS
    IMPORT DATA FOR HS CODE 300241
    EXPORT DATA FOR HS CODE 300241
  • 5.15 IMPACT OF AI/GEN AI ON CANCER VACCINES MARKET
  • 5.16 PIPELINE ANALYSIS
CANCER VACCINES MARKET, BY TYPE
91
  • 6.1 INTRODUCTION
  • 6.2 PREVENTIVE VACCINES
    NATIONAL IMMUNIZATION PROGRAMS & BIOTECHNOLOGY INNOVATIONS TO DRIVE MARKET GROWTH
  • 6.3 THERAPEUTIC VACCINES
    NEOANTIGEN CANCER VACCINES
    - Personalized nature of neoantigen cancer vaccines to propel market growth
    OTHER THERAPEUTIC VACCINES
CANCER VACCINES MARKET, BY TECHNOLOGY
106
  • 7.1 INTRODUCTION
  • 7.2 CELL-BASED VACCINES
    ADVANCEMENTS IN MANUFACTURING PROCESSES TO DRIVE MARKET GROWTH
  • 7.3 RECOMBINANT VACCINES
    GLOBAL VACCINATION INITIATIVES TO PROPEL MARKET
  • 7.4 OTHER VACCINE TECHNOLOGIES
CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION
117
  • 8.1 INTRODUCTION
  • 8.2 INTRAMUSCULAR ROUTE
    TECHNOLOGICAL ADVANCEMENTS IN VACCINE DELIVERY TO SUPPORT MARKET GROWTH
  • 8.3 OTHER ROUTES OF ADMINISTRATION
CANCER VACCINES MARKET, BY INDICATION
125
  • 9.1 INTRODUCTION
  • 9.2 CERVICAL & RELATED CANCERS
    RISING CERVICAL CANCER PREVALENCE TO SUPPORT MARKET GROWTH
  • 9.3 OTHER INDICATIONS
CANCER VACCINES MARKET, BY END USER
133
  • 10.1 INTRODUCTION
  • 10.2 HOSPITALS
    RISING CANCER PREVALENCE TO SUPPORT MARKET GROWTH
  • 10.3 SPECIALTY CLINICS & CENTERS
    INCREASING AWARENESS AND ACCESS TO PROPEL MARKET
CANCER VACCINES MARKET, BY REGION
141
  • 11.1 INTRODUCTION
  • 11.2 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Government support & strategic initiatives by key players to strengthen biotechnology sector in China
    JAPAN
    - Government initiatives for vaccines to boost market
    INDIA
    - Growth of biotechnology sector and development of new vaccines to drive market
    SOUTH KOREA
    - Commitment to cancer immunotherapy to expand cancer vaccine sector
    REST OF ASIA PACIFIC
  • 11.3 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - US to dominate North American market during forecast period
    CANADA
    - Increasing government funding for vaccine research to drive market growth in Canada
  • 11.4 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - Increasing investments by key players and growing funding from government organizations to drive market
    UK
    - Rising investments in vaccine development to boost market growth
    FRANCE
    - Support for biotechnology and research to drive market growth
    ITALY
    - Government initiatives for vaccine development to boost market growth
    SPAIN
    - Increasing investments in vaccine development by government and private organizations to support market growth
    REST OF EUROPE
  • 11.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Proactive healthcare policies to support market growth
    MEXICO
    - Government commitment to immunization programs to fuel growth
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    GCC COUNTRIES
    REST OF MIDDLE EAST
  • 11.7 AFRICA
    INCREASING INVESTMENTS IN CANCER VACCINE IMMUNIZATION PROGRAMS TO SUPPORT MARKET GROWTH
    MACROECONOMIC OUTLOOK FOR AFRICA
COMPETITIVE LANDSCAPE
210
  • 12.1 OVERVIEW
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023
    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CANCER VACCINES MARKET
  • 12.3 REVENUE ANALYSIS, 2019–2023
  • 12.4 MARKET RANKING, 2023 AND 2032
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company footprint
    - Region footprint
    - Type footprint
    - Technology footprint
    - Route of administration footprint
  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 12.7 COMPANY VALUATION & FINANCIAL METRICS
    FINANCIAL METRICS
    COMPANY VALUATION
  • 12.8 BRAND/PRODUCT COMPARISON
  • 12.9 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES & APPROVALS
    DEALS
    EXPANSIONS
COMPANY PROFILES
225
  • 13.1 KEY PLAYERS
    MERCK & CO., INC.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    GSK PLC.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    DENDREON PHARMACEUTICALS LLC. (SANPOWER GROUP)
    - Business overview
    - Products offered
    - MnM view
    JW CREAGENE (JW SHINYAK)
    - Business overview
    - Products offered
    SERUM INSTITUTE OF INDIA PVT. LTD.
    - Business overview
    - Products offered
    - Recent developments
    VERITY PHARMACEUTICALS, INC.
    - Business overview
    - Products offered
    - Recent developments
    WANTAI BIOPHARM
    - Business overview
    - Products offered
    SHANGHAI ZERUN BIOTECH CO., LTD. (WALVAX BIOTECHNOLOGY CO., LTD.)
    - Business overview
    - Products offered
    - Recent developments
    VACCINOGEN
    - Business overview
    - Products offered
  • 13.2 OTHER PLAYERS (COMPANIES WITH PRODUCTS UNDER CLINICAL STUDIES)
    BIONTECH
    - BioNTech: Products under clinical studies
    GRITSTONE BIO
    - Gritstone Bio: Products under clinical studies
    OSE-IMMUNO
    - OSE-Immuno: Products under clinical studies
    OBI PHARMA
    - OBI Pharma: Products under clinical studies
    SHANGHAI BOVAX BIOTECHNOLOGY CO., LTD.
    - Shanghai Bovax Biotechnology: Products under clinical studies
    MODERNA INC.
    - Moderna: Products under clinical studies
    BEIJING SINOCELL BIOTECHNOLOGY GROUP CO., LTD.
    - Beijing Sinocell Biotechnology Group: Products under clinical studies
    GREENWICH LIFESCIENCES, INC.
    - Greenwich LifeSciences: Products under clinical studies
    ASTON SCI. INC.
    - Aston Sci.: Products under clinical studies
    TRANSGENE
    - Transgene: Products under clinical studies
    SELLAS LIFE SCIENCES GROUP INC.
    - Sellas Life Sciences Group: Products under clinical studies
APPENDIX
254
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • TABLE 2 CANCER VACCINES MARKET: RISK ASSESSMENT ANALYSIS
  • TABLE 3 KEY RAW MATERIAL PROVIDERS IN CANCER VACCINES MARKET
  • TABLE 4 KEY PRODUCT PROVIDERS IN CANCER VACCINES MARKET
  • TABLE 5 KEY END USERS IN CANCER VACCINES MARKET
  • TABLE 6 KEY REGULATORY BODIES IN CANCER VACCINES MARKET
  • TABLE 7 NUMBER OF PATENTS FILED IN CANCER VACCINES MARKET, BY DOCUMENT TYPE, 2014–2024
  • TABLE 8 LIST OF PATENTS IN CANCER VACCINES MARKET, 2023–2024
  • TABLE 9 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY TYPE, 2021–2023
  • TABLE 10 AVERAGE SELLING PRICE OF CANCER VACCINES, BY REGION, 2023
  • TABLE 11 KEY CONFERENCES & EVENTS, JUNE 2024–DECEMBER 2025
  • TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 CANCER VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
  • TABLE 19 KEY BUYING CRITERIA FOR TOP THREE END USERS
  • TABLE 20 IMPORT VALUE FOR HS CODE 300241, 2019–2023 (USD THOUSAND)
  • TABLE 21 IMPORT VOLUME FOR HS CODE 300241, 2019–2023 (TONS)
  • TABLE 22 EXPORT VALUE FOR HS CODE 300241, 2019–2023 (USD THOUSAND)
  • TABLE 23 EXPORT VOLUME FOR HS CODE 300241, 2019–2023 (TONS)
  • TABLE 24 CANCER VACCINES MARKET: PRODUCTS IN PIPELINE AND LAUNCH DATES
  • TABLE 25 CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 26 PREVENTIVE CANCER VACCINES MARKET, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 27 NORTH AMERICA: PREVENTIVE CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 28 EUROPE: PREVENTIVE CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 29 ASIA PACIFIC: PREVENTIVE CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 30 LATIN AMERICA: PREVENTIVE CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 31 MIDDLE EAST: PREVENTIVE CANCER VACCINES MARKET, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 32 THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 33 THERAPEUTIC CANCER VACCINES MARKET, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 34 NORTH AMERICA: THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 35 EUROPE: THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 36 ASIA PACIFIC: THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 37 LATIN AMERICA: THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 38 MIDDLE EAST: THERAPEUTIC CANCER VACCINES MARKET, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 39 NEOANTIGEN CANCER VACCINES MARKET, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 40 NORTH AMERICA: NEOANTIGEN CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 41 EUROPE: NEOANTIGEN CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 42 ASIA PACIFIC: NEOANTIGEN CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 43 LATIN AMERICA: NEOANTIGEN CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 44 MIDDLE EAST: NEOANTIGEN CANCER VACCINES MARKET, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 45 OTHER THERAPEUTIC CANCER VACCINES MARKET, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 46 NORTH AMERICA: OTHER THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 47 EUROPE: OTHER THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 48 ASIA PACIFIC: OTHER THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 49 LATIN AMERICA: OTHER THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 50 MIDDLE EAST: OTHER THERAPEUTIC CANCER VACCINES MARKET, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 51 CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 52 CELL-BASED CANCER VACCINES MARKET, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 53 NORTH AMERICA: CELL-BASED CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 54 EUROPE: CELL-BASED CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 55 ASIA PACIFIC: CELL-BASED CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 56 LATIN AMERICA: CELL-BASED CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 57 MIDDLE EAST: CELL-BASED CANCER VACCINES MARKET, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 58 RECOMBINANT CANCER VACCINES MARKET, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 59 NORTH AMERICA: RECOMBINANT CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 60 EUROPE: RECOMBINANT CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 61 ASIA PACIFIC: RECOMBINANT CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 62 LATIN AMERICA: RECOMBINANT CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 63 MIDDLE EAST: RECOMBINANT CANCER VACCINES MARKET, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 64 OTHER CANCER VACCINE TECHNOLOGIES MARKET, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 65 NORTH AMERICA: OTHER CANCER VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 66 EUROPE: OTHER CANCER VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 67 ASIA PACIFIC: OTHER CANCER VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 68 LATIN AMERICA: OTHER CANCER VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 69 MIDDLE EAST: OTHER CANCER VACCINE TECHNOLOGIES MARKET, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 70 CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 71 CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 72 NORTH AMERICA: CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 73 EUROPE: CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 74 ASIA PACIFIC: CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 75 LATIN AMERICA: CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 76 MIDDLE EAST: CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 77 CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 78 NORTH AMERICA: CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 79 EUROPE: CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 80 ASIA PACIFIC: CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 81 LATIN AMERICA: CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 82 MIDDLE EAST: CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 83 CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 84 CERVICAL & RELATED CANCER VACCINES MARKET, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 85 NORTH AMERICA: CERVICAL & RELATED CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 86 EUROPE: CERVICAL & RELATED CANCER VACCINES MARKET, BY COUNTRY, 2022–2032(USD MILLION)
  • TABLE 87 ASIA PACIFIC: CERVICAL & RELATED CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 88 LATIN AMERICA: CERVICAL & RELATED CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 89 MIDDLE EAST: CERVICAL & RELATED CANCER VACCINES MARKET, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 90 CANCER VACCINES MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 91 NORTH AMERICA: CANCER VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 92 EUROPE: CANCER VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032(USD MILLION)
  • TABLE 93 ASIA PACIFIC: CANCER VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 94 LATIN AMERICA: CANCER VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 95 MIDDLE EAST: CANCER VACCINES MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 96 CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 97 CANCER VACCINES MARKET FOR HOSPITALS, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 98 NORTH AMERICA: CANCER VACCINES MARKET FOR HOSPITALS, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 99 EUROPE: CANCER VACCINES MARKET FOR HOSPITALS, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 100 ASIA PACIFIC: CANCER VACCINES MARKET FOR HOSPITALS, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 101 LATIN AMERICA: CANCER VACCINES MARKET FOR HOSPITALS, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 102 MIDDLE EAST: CANCER VACCINES MARKET FOR HOSPITALS, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 103 CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 104 NORTH AMERICA: CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 105 EUROPE: CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 106 ASIA PACIFIC: CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 107 LATIN AMERICA: CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 108 MIDDLE EAST: CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 109 CANCER VACCINES MARKET, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 110 ASIA PACIFIC: KEY MACROINDICATORS
  • TABLE 111 ASIA PACIFIC: CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 112 ASIA PACIFIC: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 113 ASIA PACIFIC: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 114 ASIA PACIFIC: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 115 ASIA PACIFIC: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 116 ASIA PACIFIC: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 118 CHINA: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 119 CHINA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 120 CHINA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 121 CHINA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 122 CHINA: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 123 CHINA: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 124 JAPAN: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 125 JAPAN: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 126 JAPAN: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 127 JAPAN: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 128 JAPAN: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 129 JAPAN: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 130 INDIA: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 131 INDIA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 132 INDIA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 133 INDIA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 134 INDIA: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 135 INDIA: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 136 SOUTH KOREA: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 137 SOUTH KOREA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 138 SOUTH KOREA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 139 SOUTH KOREA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 140 SOUTH KOREA: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 141 SOUTH KOREA: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 142 REST OF ASIA PACIFIC: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 143 REST OF ASIA PACIFIC: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 144 REST OF ASIA PACIFIC: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 145 REST OF ASIA PACIFIC: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 146 REST OF ASIA PACIFIC: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 147 REST OF ASIA PACIFIC: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 148 NORTH AMERICA: KEY MACROINDICATORS
  • TABLE 149 NORTH AMERICA: CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 150 NORTH AMERICA: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 151 NORTH AMERICA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 152 NORTH AMERICA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 153 NORTH AMERICA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 154 NORTH AMERICA: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 155 NORTH AMERICA: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 156 US: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 157 US: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 158 US: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 159 US: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 160 US: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 161 US: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 162 CANADA: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 163 CANADA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 164 CANADA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 165 CANADA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 166 CANADA: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 167 CANADA: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 168 EUROPE: KEY MACROINDICATORS
  • TABLE 169 EUROPE: CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 170 EUROPE: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 171 EUROPE: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 172 EUROPE: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 173 EUROPE: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 174 EUROPE: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 175 EUROPE: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 176 GERMANY: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 177 GERMANY: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 178 GERMANY: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 179 GERMANY: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 180 GERMANY: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 181 GERMANY: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 182 UK: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 183 UK: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 184 UK: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 185 UK: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 186 UK: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 187 UK: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 188 FRANCE: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 189 FRANCE: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 190 FRANCE: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 191 FRANCE: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 192 FRANCE: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 193 FRANCE: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 194 ITALY: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 195 ITALY: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 196 ITALY: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 197 ITALY: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 198 ITALY: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 199 ITALY: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 200 SPAIN: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 201 SPAIN: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 202 SPAIN: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 203 SPAIN: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 204 SPAIN: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 205 SPAIN: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 206 REST OF EUROPE: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 207 REST OF EUROPE: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 208 REST OF EUROPE: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 209 REST OF EUROPE: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 210 REST OF EUROPE: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 211 REST OF EUROPE: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 212 LATIN AMERICA: KEY MACROINDICATORS
  • TABLE 213 LATIN AMERICA: CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
  • TABLE 214 LATIN AMERICA: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 215 LATIN AMERICA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 216 LATIN AMERICA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 217 LATIN AMERICA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 218 LATIN AMERICA: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 219 LATIN AMERICA: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 220 BRAZIL: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 221 BRAZIL: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 222 BRAZIL: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 223 BRAZIL: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 224 BRAZIL: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 225 BRAZIL: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 226 MEXICO: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 227 MEXICO: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 228 MEXICO: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 229 MEXICO: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 230 MEXICO: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 231 MEXICO: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 232 REST OF LATIN AMERICA: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 233 REST OF LATIN AMERICA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 234 REST OF LATIN AMERICA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 235 REST OF LATIN AMERICA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 236 REST OF LATIN AMERICA: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 237 REST OF LATIN AMERICA: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 238 MIDDLE EAST: KEY MACROINDICATORS
  • TABLE 239 MIDDLE EAST: CANCER VACCINES MARKET, BY REGION, 2022–2032 (USD MILLION)
  • TABLE 240 MIDDLE EAST: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 241 MIDDLE EAST: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 242 MIDDLE EAST: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 243 MIDDLE EAST: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 244 MIDDLE EAST: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 245 MIDDLE EAST: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 246 GCC COUNTRIES: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 247 GCC COUNTRIES: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 248 GCC COUNTRIES: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 249 GCC COUNTRIES: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 250 GCC COUNTRIES: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 251 GCC COUNTRIES: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 252 REST OF MIDDLE EAST: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 253 REST OF MIDDLE EAST: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 254 REST OF MIDDLE EAST: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 255 REST OF MIDDLE EAST: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 256 REST OF MIDDLE EAST: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 257 REST OF MIDDLE EAST: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 258 AFRICA: KEY MACROINDICATORS
  • TABLE 259 AFRICA: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 260 AFRICA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION)
  • TABLE 261 AFRICA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION)
  • TABLE 262 AFRICA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION)
  • TABLE 263 AFRICA: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION)
  • TABLE 264 AFRICA: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION)
  • TABLE 265 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, 2021-2024
  • TABLE 266 CANCER VACCINES MARKET SHARE RANKING (2023)
  • TABLE 267 CANCER VACCINES MARKET SHARE RANKING (2032)
  • TABLE 268 CANCER VACCINES MARKET: REGION FOOTPRINT
  • TABLE 269 CANCER VACCINES MARKET: TYPE FOOTPRINT
  • TABLE 270 CANCER VACCINES MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 271 CANCER VACCINES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
  • TABLE 272 CANCER VACCINES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 273 CANCER VACCINES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 274 CANCER VACCINES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 275 CANCER VACCINES MARKET: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 276 CANCER VACCINES MARKET: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
  • TABLE 277 MERCK: COMPANY OVERVIEW
  • TABLE 278 MERCK: PRODUCTS OFFERED
  • TABLE 279 MERCK: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 280 MERCK: EXPANSIONS, JANUARY 2021–NOVEMBER 2024
  • TABLE 281 GSK: COMPANY OVERVIEW
  • TABLE 282 GSK: PRODUCTS OFFERED
  • TABLE 283 GSK: PRODUCT APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 284 DENDREON PHARMACEUTICALS: COMPANY OVERVIEW
  • TABLE 285 DENDREON PHARMACEUTICALS: PRODUCTS OFFERED
  • TABLE 286 JW CREAGENE: COMPANY OVERVIEW
  • TABLE 287 JW CREAGENE: PRODUCTS OFFERED
  • TABLE 288 SERUM INSTITUTE OF INDIA: COMPANY OVERVIEW
  • TABLE 289 SERUM INSTITUTE OF INDIA: PRODUCTS OFFERED
  • TABLE 290 SERUM INSTITUTE OF INDIA: PRODUCT LAUNCHES, JANUARY 2021–NOVEMBER 2024
  • TABLE 291 SERUM INSTITUTE OF INDIA: DEALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 292 VERITY PHARMACEUTICALS: COMPANY OVERVIEW
  • TABLE 293 VERITY PHARMACEUTICALS: PRODUCTS OFFERED
  • TABLE 294 VERITY PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 295 WANTAI BIOPHARM: COMPANY OVERVIEW
  • TABLE 296 WANTAI BIOPHARM: PRODUCTS OFFERED
  • TABLE 297 SHANGHAI ZERUN BIOTECHNOLOGY: COMPANY OVERVIEW
  • TABLE 298 SHANGHAI ZERUN BIOTECHNOLOGY: PRODUCTS OFFERED
  • TABLE 299 SHANGHAI ZERUN BIOTECHNOLOGY: PRODUCT APPROVALS, JANUARY 2021–NOVEMBER 2024
  • TABLE 300 VACCINOGEN: COMPANY OVERVIEW
  • TABLE 301 VACCINOGEN: PRODUCTS OFFERED
LIST OF FIGURES
 
  • FIGURE 1 CANCER VACCINES MARKET SEGMENTATION
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARIES: CANCER VACCINES MARKET
  • FIGURE 4 CANCER VACCINES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
  • FIGURE 5 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (PRODUCTS), 2023
  • FIGURE 6 ILLUSTRATIVE EXAMPLE OF MERCK & CO., INC.: REVENUE SHARE ANALYSIS (2023)
  • FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 9 CANCER VACCINES MARKET: CAGR PROJECTIONS
  • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • FIGURE 11 CANCER VACCINES MARKET, BY TYPE, 2024 VS. 2032 (USD MILLION)
  • FIGURE 12 CANCER VACCINES MARKET, BY TECHNOLOGY, 2024 VS. 2032 (USD MILLION)
  • FIGURE 13 CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2024 VS. 2032 (USD MILLION)
  • FIGURE 14 CANCER VACCINES MARKET, BY INDICATION, 2024 VS. 2032 (USD MILLION)
  • FIGURE 15 CANCER VACCINES MARKET, BY END USER, 2024 VS. 2032 (USD MILLION)
  • FIGURE 16 GEOGRAPHICAL SNAPSHOT OF CANCER VACCINES MARKET (2024–2032)
  • FIGURE 17 ADVANCEMENTS IN CANCER VACCINES AND RISING DEMAND FOR NEOANTIGEN CANCER VACCINES TO DRIVE MARKET
  • FIGURE 18 RECOMBINANT VACCINES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 19 PREVENTIVE VACCINES TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 20 US TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 21 CANCER VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 22 TRENDS/DISRUPTIONS INFLUENCING CUSTOMERS’ BUSINESS
  • FIGURE 23 CANCER VACCINES MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 24 CANCER VACCINES MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 25 CANCER VACCINES MARKET: PATENT ANALYSIS
  • FIGURE 26 CANCER VACCINES MARKET: FUNDING SCENARIO
  • FIGURE 27 CANCER VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 28 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS
  • FIGURE 29 KEY BUYING CRITERIA FOR TOP END USERS
  • FIGURE 30 CANCER VACCINES MARKET: IMPACT OF AI
  • FIGURE 31 ASIA PACIFIC: CANCER VACCINES MARKET SNAPSHOT
  • FIGURE 32 NORTH AMERICA: CANCER VACCINES MARKET SNAPSHOT
  • FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN CANCER VACCINES MARKET, 2019–2023
  • FIGURE 34 CANCER VACCINES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 35 CANCER VACCINES MARKET: COMPANY FOOTPRINT
  • FIGURE 36 CANCER VACCINES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 37 EV/EBITDA OF KEY VENDORS
  • FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 39 CANCER VACCINES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 40 MERCK: COMPANY SNAPSHOT (2023)
  • FIGURE 41 GSK: COMPANY SNAPSHOT (2023)

The research study involved the wide use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global cancer vaccines market. Extensive interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level managers of leading market players, and industry consultants, to obtain and verify qualitative and quantitative information and evaluate the growth scenarios of the market. The global market size estimated through secondary research (top down and bottom-up) followed by data triangulation with inputs from industry experts to arrive at the final market size.

Secondary Research

Secondary research was used mainly to identify and collect information for the technical, market-oriented, and commercial study of the cancer vaccines market. The secondary sources used for this study include National Cancer Institute (NCI), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), National Institute of Allergy and Infectious Diseases (NIAID), International Society for Vaccines (ISV), United Nations Children’s Fund (UNICEF), GAVI, Pan American Health Organization (PAHO), Medical Research Council (MRC), World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations among others. These secondary sources were also used to obtain major information about key market players, and market segmentation corresponding to industry trends, regional/country-level markets, market developments, and technology prospects. Secondary data was collected and analysed to arrive at the market size of the global cancer vaccines market, which was further validated through primary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global cancer vaccines market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical & biopharmaceutical industries from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. The primary interviews were conducted across six major regions, including the North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Approximately 65% and 35% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

Cancer Vaccines Market

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the cancer vaccines market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Cancer Vaccines Market

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Cancer vaccines are biopharmaceutical products designed to prevent or treat cancer by stimulating the body's immune system to recognize and attack cancer cells. Cancer vaccines are categorized as preventive (e.g., HPV and hepatitis B vaccines to prevent cancer-causing infections) or therapeutic, which aim to treat existing cancers. Therapeutic vaccines may use tumor-associated antigens, personalized neoantigens, or immune-stimulating components like adjuvants to enhance efficacy. In the report we have considered FDA and other regional regulatory body approved products as cancer vaccines.

Stakeholders

  • Companies Providing Cancer vaccines
  • Research Institutes and Academic Centers
  • Pharmaceutical and Biotechnology Companies
  • Regulatory Authorities
  • Healthcare Providers
  • Patients and Patient Advocacy Groups
  • Public Health Agencies
  • Business Research and Consulting Service Providers
  • Venture Capitalists
  • Contract Research Organizations and Contract Development Manufacturing Organizations
  • Market research and consulting firms

Report Objectives

  • To define, describe, and forecast the Cancer vaccines market by value by type, technology, route of administration, indications, end users, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall cancer vaccines market
  • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to six regions: North America, Europe, the Asia Pacific, Latin America, Middle East and Africa
  • To profile the key players and analyze their market shares and core competencies2
  • To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
  • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

 

Previous Versions of this Report

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Cancer Vaccines Market

DMCA.com Protection Status